What's behind Sanofi's latest 5.4% stock pullback?

Traders Union
All News
Stocks
Sanofi drops 5.37% today to $42.44

Highlights

Sanofi raised its 2026 outlook after robust first-half sales of €22.1 billion and strong Dupixent demand.
Earnings growth was accompanied by a €1 billion share buyback, €4.12 dividend announcement, and a significant €1 billion amlitelimab-related impairment.
Shares trade under technical pressure with a bearish long-term trend, key resistance at €42.48, and an expected five-day range of €41.09–€43.79.

Impairment charges and buyback shape sentiment despite upbeat forecast

Sanofi reported first-half 2026 sales of €22.1 billion and second-quarter net sales of €11.6 billion. A €1 billion impairment related to amlitelimab and the Dynavax acquisition was disclosed, alongside a completed €1 billion share buyback and a €4.12 per share dividend for 2025. The outlook for 2026 was raised on strong demand for Dupixent and other medicines, with business EPS, operating income, and free cash flow also recording substantial gains, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees Sanofi under sustained downside pressure following asset impairments and negative investor sentiment. He highlights that trading below the 20-, 50-, and 200-day averages reinforces technical weakness. Momentum indicators remain conflicted, raising concerns about near-term volatility. Kharitonov notes that despite positive business results, the €1 billion impairment and pipeline changes undermine confidence. "Unless price reclaims €42.48 with clear volume, I consider Sanofi vulnerable to further declines," he says.

Viktoras Karapetjanc, expert at Traders Union, maintains a constructive outlook on Sanofi. He emphasizes the company’s raised 2026 guidance and robust sales growth, driven by strong Dupixent demand. Karapetjanc sees recent buybacks and increased dividends as reinforcing shareholder value. He argues that market volatility provides opportunity near support. "The bullish structure remains intact, and I expect further growth with upside potential above €42.48," he states.

Sholanke Dele, market strategist, remains skeptical about Sanofi’s short-term momentum. Dele points out that the €1 billion impairment and acquisition costs reflect deeper strategic issues. He notes that price action suggests weak sentiment, with broad selling pressure outweighing earnings gains. "Without a catalyst to reverse sentiment, I remain cautious on Sanofi’s outlook this week," Dele says.

Bearish long-term trend amid mixed momentum and elevated volatility

Sanofi is trading below its 20-, 50-, and 200-day moving averages at $43.65, $43.54, and $46.56 respectively, pointing to sustained downward pressure over the short, medium, and long term. The nearest resistance is at $42.48 and support is at $41.47, with a continued bearish long-term trend. Technical momentum is mixed: MACD, RSI, and the Awesome Oscillator suggest buying momentum, but the CCI and Bull/Bear Power highlight overbought conditions with intraday buying dominance. The ADX remains neutral, and Stochastic RSI issues a strong sell. Divergence across momentum indicators adds to near-term uncertainty, while intraday volatility is elevated at 2.44%.

Earlier, analysts noted that regulatory shifts and leadership changes at the FDA were contributing to a more favorable environment for biotech innovation and approvals, benefiting large pharmaceutical companies such as Sanofi. The latest technical and fundamental signals, however, highlight increased volatility and reinforce the importance of monitoring price action near the $41.47 support for signs of further downside risk or a potential reversal.

Source of Data: SNY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.